Effects of antiviral therapy on the production of anti-human immunodeficiency virus-specific immunoglobulin in infants and children.
The effect of zidovudine therapy on human immunodeficiency virus (HIV)-specific antibody production was studied in 64 HIV-1-infected infants and children > 6 months old. HIV-specific in vitro antibody production (IVAP) was measured in cultures of peripheral blood mononuclear cells (PBMC). IVAP decreased in 85% of children after zidovudine was initiated (mean decline, 1 log within 2 months). Effects were seen as early as 1 week after starting zidovudine. No change in IVAP was seen in children not treated. In comparison, plasma core (p24) antigen levels declined and CD4+ lymphocytes increased in only 42% and 52%, respectively, of treated subjects. Thus, the production of antibody to HIV-1 decreases rapidly after the initiation of antiretroviral therapy. This response to therapy may provide a simple and sensitive method of monitoring antiretroviral therapy.
Pollack
H
H
Department of Pediatrics, New York University Medical Center, NY 10016.
Zhan
M X
MX
Moore
T
T
Tao
P Z
PZ
Krasinski
K
K
Borkowsky
W
W
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000635:transmission; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D015483:HIV Antibodies / Q000096:biosynthesis* / Q000097:blood; D016655:HIV Core Protein p24 / Q000097:blood; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical; D008214:Lymphocytes / Q000276:immunology; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D016176:T-Lymphocyte Subsets / Q000276:immunology; D015215:Zidovudine / Q000627:therapeutic use*
D015483:HIV Antibodies; D016655:HIV Core Protein p24; D015215:Zidovudine